IDH2 and glioblastoma: Compared to IDH-wild-type glioblastoma from the same publicly available cohorts (n = 983); however, subclonal IDH-mutant astrocytomas had significantly better progression-free survival (P < .0001) and OS (P = .0005) (Supplementary Figure 1).